F M Investments LLC Buys Shares of 61,782 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

F M Investments LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 61,782 shares of the specialty pharmaceutical company's stock, valued at approximately $3,686,000. F M Investments LLC owned about 0.29% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in ANI Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock worth $90,314,000 after buying an additional 17,460 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of ANI Pharmaceuticals by 3.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock worth $40,132,000 after acquiring an additional 21,053 shares during the last quarter. Millennium Management LLC boosted its stake in shares of ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock worth $14,651,000 after purchasing an additional 209,272 shares during the period. Thompson Siegel & Walmsley LLC grew its holdings in ANI Pharmaceuticals by 1.5% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 195,743 shares of the specialty pharmaceutical company's stock valued at $12,465,000 after purchasing an additional 2,986 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in ANI Pharmaceuticals by 149.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company's stock worth $11,107,000 after purchasing an additional 111,613 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Up 1.7 %

Shares of ANIP stock traded up $0.95 on Friday, hitting $58.19. The stock had a trading volume of 241,171 shares, compared to its average volume of 180,750. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The business has a 50 day moving average price of $59.13 and a 200 day moving average price of $61.77. The company has a market cap of $1.22 billion, a PE ratio of 49.74 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. The business had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company's quarterly revenue was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 EPS. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ANIP. StockNews.com cut ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Truist Financial upped their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research report on Tuesday, October 22nd. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a report on Wednesday, September 18th. Finally, Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.